It is the first time that we verified co-activation of NF-κB and EZH2 confers the poorest clinic outcome and the risk and prognosis of glioblastoma can be reliably stratified according to the expression of EZH2 and p65 [low-risk: low p65 and EZH2 expression; intermediate-risk: high either p65 or EZH2 expression; and high-risk: high p65 and EZH2 expression; DFS and OS (p < 0.0001)]. The gene discussed is NFKB1; the disease is glioblastoma.